Dyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of HAE attacks
Posted on10 Jul 2015
Comments0
Dyax Corp. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the investigation of DX-2930 for hereditary... Read More